These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11878581)

  • 1. Modified cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone therapy for posttransplantation lymphoproliferative disease in pediatric patients undergoing solid organ transplantation.
    Suryanarayan K; Natkunam Y; Berry G; Bangs CD; Cherry A; Dahl G
    J Pediatr Hematol Oncol; 2001 Oct; 23(7):452-5. PubMed ID: 11878581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Posttransplantation lymphoproliferative disorders treated with cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy.
    Garrett TJ; Chadburn A; Barr ML; Drusin RE; Chen JM; Schulman LL; Smith CR; Reison DS; Rose EA; Michler RE
    Cancer; 1993 Nov; 72(9):2782-5. PubMed ID: 8402504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab therapy and reduction of immunosuppression to rescue graft function after renal posttransplantation lymphoproliferative disorder found by macrohematuria in a pancreas and kidney transplant recipient: a case report.
    Miyagi S; Sekiguchi S; Kawagishi N; Akamatsu Y; Satoh K; Takeda I; Fukushima D; Kobayashi Y; Tokodai K; Fujimori K; Satomi S
    Transplant Proc; 2011 Nov; 43(9):3299-301. PubMed ID: 22099782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world Outcomes With Rituximab-based Therapy for Posttransplant Lymphoproliferative Disease Arising After Solid Organ Transplant.
    Burns DM; Clesham K; Hodgson YA; Fredrick L; Haughton J; Lannon M; Hussein H; Shin JS; Hollows RJ; Robinson L; Byrne C; McNamara C; Vydianath B; Lennard AL; Fields P; Johnson R; Wright J; Fox CP; Cwynarski K; Chaganti S
    Transplantation; 2020 Dec; 104(12):2582-2590. PubMed ID: 33104308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EBV and posttransplantation lymphoproliferative disease: what to do?
    Zimmermann H; Trappe RU
    Hematology Am Soc Hematol Educ Program; 2013; 2013():95-102. PubMed ID: 24319169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short-course EPOCH regimens are safe and effective.
    Rubinstein JD; Shah R; Breese EH; Burns KC; Mangino JL; Norris RE; Lee L; Mizukawa B; O'Brien MM; Phillips CL; Perentesis JP; Pommert L; Absalon MJ
    Pediatr Blood Cancer; 2021 Aug; 68(8):e29126. PubMed ID: 34019326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation.
    Gross TG; Bucuvalas JC; Park JR; Greiner TC; Hinrich SH; Kaufman SS; Langnas AN; McDonald RA; Ryckman FC; Shaw BW; Sudan DL; Lynch JC
    J Clin Oncol; 2005 Sep; 23(27):6481-8. PubMed ID: 16170157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
    Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
    Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen.
    Fohrer C; Caillard S; Koumarianou A; Ellero B; Woehl-Jaeglé ML; Meyer C; Epailly E; Chenard MP; Lioure B; Natarajan-Ame S; Maloisel F; Lutun P; Kessler R; Moulin B; Bergerat JP; Wolf P; Herbrecht R
    Br J Haematol; 2006 Sep; 134(6):602-12. PubMed ID: 16889621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.
    Trappe RU; Dierickx D; Zimmermann H; Morschhauser F; Mollee P; Zaucha JM; Dreyling MH; Dührsen U; Reinke P; Verhoef G; Subklewe M; Hüttmann A; Tousseyn T; Salles G; Kliem V; Hauser IA; Tarella C; Van Den Neste E; Gheysens O; Anagnostopoulos I; Leblond V; Riess H; Choquet S
    J Clin Oncol; 2017 Feb; 35(5):536-543. PubMed ID: 27992268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
    Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU
    Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in chemotherapy for large cell lymphoma.
    Coleman M; Gerstein G; Topilow A; Lebowicz J; Berhardt B; Chiarieri D; Silver RT; Pasmantier MW
    Semin Hematol; 1987 Apr; 24(2 Suppl 1):8-20. PubMed ID: 2438781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DA-EPOCH-R for post-transplant lymphoproliferative disorders.
    DeStefano CB; Malkovska V; Rafei H; Shenoy A; Fitzpatrick K; Aggarwal A; Catlett JP
    Eur J Haematol; 2017 Sep; 99(3):283-285. PubMed ID: 28509395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation.
    Choquet S; Trappe R; Leblond V; Jäger U; Davi F; Oertel S
    Haematologica; 2007 Feb; 92(2):273-4. PubMed ID: 17296588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTLD treatment: a step forward, a long way to go.
    Montserrat E
    Lancet Oncol; 2012 Feb; 13(2):120-1. PubMed ID: 22173061
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials.
    Zimmermann H; Babel N; Dierickx D; Morschhauser F; Mollee P; Zaucha JM; Dreyling MH; Dührsen U; Reinke P; Verhoef G; Subklewe M; Hüttmann A; Tousseyn T; Bachy E; Hauser IA; Tarella C; Van Den Neste E; Gheysens O; Anagnostopoulos I; Leblond V; Riess H; Choquet S; Trappe RU
    Transplantation; 2018 Nov; 102(11):1914-1923. PubMed ID: 29757894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibrutinib as part of risk-stratified treatment for posttransplant lymphoproliferative disorder: the phase 2 TIDaL trial.
    Chaganti S; Maycock S; McIlroy G; Jackson A; Bishop R; Johnson S; Kanfer E; Kassam S; Cwynarski K; Wrench D; Arumainathan A; Fox CP; Johnson R; McKay P; Paneesha S; Rowntree C; Balotis C; Collins GP; Davies A; Wright J; Burns S; Laurence A; Wheatley K; Menne T
    Blood; 2024 Jul; 144(4):392-401. PubMed ID: 38643491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoimmunotherapy and withdrawal of immunosuppression for monomorphic posttransplant lymphoproliferative disorders.
    Podoltsev N; Zhang B; Yao X; Bustillo I; Deng Y; Cooper DL
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):716-20. PubMed ID: 24035715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
    Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
    J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
    Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
    Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.